ClinVar Miner

Submissions for variant NM_000419.5(ITGA2B):c.1186G>A (p.Asp396Asn)

gnomAD frequency: 0.00001  dbSNP: rs1214448436
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen RCV000852005 SCV001397559 pathogenic Glanzmann thrombasthenia 2021-12-02 reviewed by expert panel curation The NM_000419.4:c.1186G>A variant that results in the missense change, Asp396Asn, is reported at a low frequency of 0.000066 in gnomAD (PM2_supporting). It is reported in three compound heterozygous (PMID: 25373348, 34267460, and 31064749) and one apparently homozygous (PMID: 19172520) probands (PM3_strong). Probands from PMID: 25373348 and 34267460 meet criteria for PP4_strong including mucocutaneous bleeding, impaired aggregation with all agonists except ristocetin, and reduced surface expression of alphaIIbbeta3 measured by flow cytometry. It is predicted damaging by in-silico tools, with a REVEL score of 0.871. In summary, there is evidence to classify the Asp396Asn variant as Pathogenic for GT. GT-specific criteria applied: PM3_strong, PM2_Supporting, PP3, PP4_Strong.
NIHR Bioresource Rare Diseases, University of Cambridge RCV000852005 SCV000899447 likely pathogenic Glanzmann thrombasthenia 2019-02-01 criteria provided, single submitter research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.